Alto Neuroscience Files 8-K Report
Ticker: ANRO · Form: 8-K · Filed: Oct 22, 2024 · CIK: 1999480
| Field | Detail |
|---|---|
| Company | Alto Neuroscience, Inc. (ANRO) |
| Form Type | 8-K |
| Filed Date | Oct 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Alto Neuroscience filed an 8-K. Check for updates.
AI Summary
On October 22, 2024, Alto Neuroscience, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or significant business events were detailed in the provided excerpt.
Why It Matters
This filing indicates that Alto Neuroscience, Inc. is making a regulatory submission to the SEC, which could contain important updates for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain information that inherently poses a high risk.
Key Players & Entities
- Alto Neuroscience, Inc. (company) — Registrant
- October 22, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-41944 (identifier) — SEC File Number
- 650 Castro Street, Suite 450, Mountain View, CA 94041 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The filing is a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting "Other Events" and "Financial Statements and Exhibits" as of October 22, 2024.
When was the earliest event reported in this filing?
The earliest event reported is dated October 22, 2024.
What is Alto Neuroscience, Inc.'s state of incorporation?
Alto Neuroscience, Inc. is incorporated in Delaware.
What is the SEC file number for Alto Neuroscience, Inc.?
The SEC file number for Alto Neuroscience, Inc. is 001-41944.
Where are Alto Neuroscience, Inc.'s principal executive offices located?
Alto Neuroscience, Inc.'s principal executive offices are located at 650 Castro Street, Suite 450, Mountain View, CA 94041.
Filing Stats: 498 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-10-22 16:35:00
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ANRO New York S
Filing Documents
- d876702d8k.htm (8-K) — 25KB
- d876702dex991.htm (EX-99.1) — 16KB
- g876702g1022211003854.jpg (GRAPHIC) — 4KB
- 0001193125-24-241092.txt ( ) — 175KB
- anro-20241022.xsd (EX-101.SCH) — 3KB
- anro-20241022_lab.xml (EX-101.LAB) — 18KB
- anro-20241022_pre.xml (EX-101.PRE) — 11KB
- d876702d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits. Exhibit No. Description 99.1 Press Release of Alto Neuroscience, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALTO NEUROSCIENCE, INC. Dated: October 22, 2024 By: /s/ Amit Etkin Amit Etkin, M.D., Ph.D. President and Chief Executive Officer